Neurodevelopmental outcomes.
| Measurement | Epilepsy | Motor | Cognitive | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Good outcome | Poor outcome | P-value | Good outcome | Poor outcome | P-value | Good outcome | Poor outcome | P-value | |
| Etiology | 0.314 | 0.003* | 0.001* | ||||||
| Unknown | 7 (13.2) | 1 (1.9) | 7 (13.2) | 1 (1.9) | 7(13.2) | 1 (1.9) | |||
| Cryptogenic | 4 (7.5) | 3 (5.7) | 2 (3.8) | 5 (9.4) | 1 (1.9) | 6 (11.3) | |||
| Symptomatic | 24 (45.3) | 14 (26.4) | 9 (17) | 29 (54.7) | 7 (13.2) | 31 (58.5) | |||
| Gender | 0.502 | 0.502 | 0.272 | ||||||
| Male | 17 (70.8) | 7 (29.2) | 7 (70.8) | 17 (29.2) | 5 (20.8) | 19 (79.2) | |||
| Female | 18 (62.0) | 11 (38.0) | 11 (38.0) | 18 (62.0) | 10 (34.5) | 19 (65.5) | |||
| Age at onset of spasms (months) | 6.30 | 10.20 | 0.138 | 7.39 | 7.63 | 0.898 | 6.87 | 7.82 | 0.628 |
| Delay in treatment (months) | 0.82 | 1.64 | 0.116 | 0.44 | 1.41 | 0.010* | 0.40 | 1.36 | 0.006* |
↵* Statistically significant